FDA-APPROVED PRODUCT THERAPY AREAS

FDA-approved Product

Therapy Areas

Sanofi’s rare blood disorder franchise is focused on hemophilia A and B, acquired thrombotic thrombocytopenic purpura (aTTP), and cold agglutinin disease (CAD).

Educational Resources

Hemophilia

Trends in the Hemophilia Treatment Landscape
An overview of the history of hemophilia care, currently approved therapies, the comprehensive patient care model and introduction to products currently in the hemophilia therapy pipeline.

Associated Clinical Guidelines and Recommendations
NHF MASAC | National Hemophilia Foundation Medical and Scientific Advisory Council | 2022
WFH | World Federation of Hemophilia | 2020

Immune Thrombocytopenia

An Overview of Rilzabrutinib for ITP
An overview of the ITP pathophysiology, epidemiology, burden of disease, guidelines, and phase II LUNA2 data for rilzabrutinib in ITP.

ITP Disease Overview and Therapeutic Landscape
An overview of the ITP pathophysiology, epidemiology, burden of disease, guidelines, current FDA approved therapies and pipeline agents.

Acquired Thrombotic Thrombocytopenic Purpura

ISTH Guidelines for TTP 2021
A presentation summarizing guidelines established by the International Society on Thrombosis and Haemostasis (ISTH) for the diagnosis and treatment of thrombotic thrombocytopenic purpura (TPP), including the use of caplacizumab in patients with aTTP. The presentation also describes the methodologies used to develop the guidelines.